Albendazole
Albendazole
Contact Us

We are here to help in anything you need. Please use our online system or send an email to .

Albendazole

Inquiry
Catalog Number PR54965218
CAS 54965-21-8
Structure
Description Albendazole is an anti-parasitic prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of two types of parasitic infections: neurocysticercosis and hydatid disease.
Synonyms Albenza; Eskazole; Zentel; Valbazen
IUPAC Name methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
Molecular Weight 265.33
Molecular Formula C12H15N3O2S
InChI HXHWSAZORRCQMX-UHFFFAOYSA-N
InChI Key InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
Drug Categories Acids, Acyclic; Anthelmintics; Anti-Infective Agents; Anticestodal Agents; Antihelminthic; Antimitotic Agents; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiplatyhelmintic Agents; Benzimidazole Derivatives; Benzimidazoles; Carbamates; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strong); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds, Fused-Ring; Mitosis Modulators; P-glycoprotein substrates; Tubulin Modulators
Drug Interactions Abametapir-The serum concentration of Albendazole can be increased when it is combined with Abametapir.
Abatacept-The metabolism of Albendazole can be increased when combined with Abatacept.
Abemaciclib-The metabolism of Abemaciclib can be decreased when combined with Albendazole.
Abiraterone-The serum concentration of Albendazole can be increased when it is combined with Abiraterone.
Abrocitinib-The metabolism of Abrocitinib can be decreased when combined with Albendazole.
Half-Life Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).
Isomeric SMILES CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
Type Small Molecule
Therapeutic Category Antihelmintics
Pharmacology

Indications

Albendazole is indicated for the treatment of parenchymal neurocysticercosis caused by active lesions of the pork tapeworm, Taenia solium. Additionally, it is used for treating·hydatid disease of the liver, lung·hich is linked to the larval form of the dog tapeworm, Echinococcus granulosus.

Pharmacodynamics

As a broad-spectrum anthelmintic, albendazole functions primarily by inhibiting·his inhibition disrupts cytoplasmic microtubule formation, which is essential for the energy metabolism and survival of the parasite, effectively leading·hibits poor absorption in the gastrointestinal tract, attributable to its low solubility in water. However, its oral bioavailability can be significantly enhanced when ing·h a high-fat meal, approximately containing·hich facilitates better absorption.

Metabolism

Albendazole undergoes hepatic metabolism and is rapidly converted in the liver to its primary metabolite, albendazole sulfoxide. This metabolite is further processed into albendazole sulfone and other oxidative metabolites, which have been detected in human urine, indicating·he pathways through which the drug is eliminated from the body.

Mechanism of Action

Albendazole exerts its therapeutic effects by inducing degenerative changes in the tegument and intestinal cells of parasitic worms, significantly disrupting their energy production and leading to their immobilization and death. This is achieved through its binding to the colchicine-sensitive site of tubulin, which prevents the polymerization and assembly of microtubules. Since cytoplasmic microtubules play an essential role in facilitating glucose uptake in both larval and adult stages of susceptible parasites, their disruption leads to the depletion of the parasites' glycogen reserves. Additionally, albendazole induces degenerative changes in the endoplasmic reticulum and the mitochondria of the germinal layer, along with the release of lysosomes. These alterations result in a decreased production of adenosine triphosphate (ATP), the critical energy source necessary for the survival of the helminth.

It should be noted that our service is only used for research, not for clinical use.